Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Final Medicare Coverage-With-Evidence-Development Guidance Delayed By CMS Staff Cuts

This article was originally published in The Pink Sheet Daily

Executive Summary

The CMS coverage and analysis group has had to divert its attention from finishing a CED guidance to finalizing proposed changes to the process for awarding Medicare coverage for investigational device trials, primarily due to staff cuts, says Louis Jacques, who heads the group.

You may also be interested in...



Cohesive Coverage-With-Evidence Authority Needed For Medicare, Lawmakers Told

Former CMS coverage chief Louis Jacques told House lawmakers that the agency’s authority to implement coverage-with-evidence-development policies are fragmented, hindering application of the program.

Reimbursement Briefs: Pfizer Joins Big Data Group; Part D Protected Classes; Wikipedia Partners With Cochrane Collaboration

Pfizer is among seven organizations joining the Optum Labs research collaborative; CMS Coverage and Analysis Group Director Louis Jacques moving to private sector, more news in brief.

CMS Proposes Noncoverage For Percutaneous Image-guided Lumbar Decompression

The procedure, aimed at treating lumbar spinal stenosis, is not reasonable and necessary, the Medicare agency says. A final decision is due Jan. 15.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS075018

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel